A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : CAFs / cytokines and angiogenic factors

[Related PubMed/MEDLINE]
Total Number of Papers: 19
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   CAFs  (>> Co-occurring Abbreviation)
Long Form:   cytokines and angiogenic factors
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naive Metastatic Prostate Cancer. ADT, HNMPCa, OS
2020 Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib. CI, HCC, HR, MVI, PFS, RDI
2019 Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial. ELISA, MM
2017 Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid. FGF23, PFS
2017 Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma. OS, SLD, VEGF
2017 Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma. nccRCC, OS, PFS, sgp130
2017 Prognostic implication of antitumor immunity measured by the neutrophil-lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer. GC, NLR, SDF-1
2017 Signature of cytokines and angiogenic factors (CAFs) defines a clinically distinct subgroup of gastric cancer. GC, IL, OS
2016 Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Biomarker for Bevacizumab in Colorectal Cancer Liver Metastasis: A Single-Arm, Exploratory Trial. CRCLM, DCE-MRI, PFS, PlGF, VEGF
10  2015 A plasma cytokine and angiogenic factor (CAF) analysis for selection of bevacizumab therapy in patients with metastatic colorectal cancer. ANGPTL4, CAF, HGF, HR, mCRC, OS, PFS
11  2015 Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial. CI, nccRCC, OS, PFS, TNF, VEGF
12  2012 A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. CAF, IFN-alpha, mRCC, PFS, VEGF
13  2012 A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. CAF, IFN-alpha, mRCC, PFS, VEGF
14  2012 Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study. IL, OS, PFS, PlGF, STS, sVEGFR-2
15  2012 Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma. CECs, HCC, IL, ORR, VEGF
16  2012 Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. HGF, PFS, TIMP
17  2011 Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. HNSCC, OR, PFG, PFS, SD
18  2010 Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. CP, IL, MMP-9, sVEGFR-2, VEGF
19  2010 Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. FU, mCRC, PD, PFS